# MS DCF Valuation — Investment Banking Valuation Memo
**Date: 2026-09-24 (Thursday), ~10:12 ET (verified via `TZ=America/New_York date`). Mechanical roll across all six holdings — no fresh cash-flow, margin, or M&A data found on any name since yesterday's full GEHC rebuild. The one genuinely new input is macro: the 10-year Treasury's confirmed ~5.10-5.12% close on 9/23 (highest since July 2007) starts Day 1 of a fresh attempt at this desk's own WACC-rebuild clock (a settled close above 5% held a full week forces a coordinated rebuild across every rate-sensitive model on the book) — flagged clearly below, not yet acted on.**

*Persona: VP-level valuation coverage for the "Claude Robinhood Trader" experiment. Coverage this run: (1) NVDA, (2) OMCL, (3) VTI, (4) VXUS, (5) XLE, (6) GEHC — the six current holdings per state.md's 2026-09-24 ~09:37 ET live Robinhood snapshot (NVDA $222.14, VTI $376.755, VXUS $85.665, OMCL $32.8666, XLE $62.73, GEHC $66.03). GS's 2026-09-24 ~09:5x ET screener report again ranks GEHC #1 (already held, already fully built) — no separate not-held name requires a first-time cross-vet this cycle. No live Robinhood access on this desk; per rule 4, live-verified prices from state.md take precedence over WebSearch for the six holdings.*

---

## Verdicts (top line)

| Ticker | Current Price | DCF Fair Value (base case) | Verdict |
|---|---|---|---|
| **GEHC** | $66.03 (state.md, 9/24 ~09:37 ET) | **$70.8/sh** (WACC 8.5%, g 3% — unchanged since yesterday's full rebuild) | **UNDERVALUED, gap ≈ +7.2%**, essentially unchanged from yesterday's +7.0% as price ticked down slightly. No trim, no add. |
| **NVDA** | $222.14 (-1.49%) | $206.2 (WACC 11%, g 3% — unchanged since 8/27) | **OVERVALUED, gap ≈ -7.2%**, narrowing from yesterday's -9.8% as price pulled back toward fair value. No trim, no add. |
| **XLE** | $62.73 (+0.58%, today's only green holding) | ≈ $62.8/sh (composite CVX+XOM, WACC 10.5%, long-run Brent $76 — unchanged) | **~FAIR VALUE, gap ≈ +0.1%** — the undervaluation crossover first logged 9/22 has now nearly fully closed as oil firms. One more up-tick in price flips this back to overvalued. No trim, no unilateral add. |
| **OMCL** | $32.8666 (-0.37%) | ~$53.89 (WACC 9%, g 3%, unchanged since 7/30) | **UNDERVALUED — ~64.0% upside**, essentially flat vs. yesterday's +63.1%. Next print confirmed 10/29. |
| **VTI** | $376.755 (-0.39%) | N/A — no single-company DCF applies | **NOT APPLICABLE / HOLD BY CONSTRUCTION.** |
| **VXUS** | $85.665 (-0.30%) | N/A — no single-company DCF applies | **NOT APPLICABLE / HOLD BY CONSTRUCTION.** |

**Bottom line for the trader:** A quiet mechanical-roll day on cash flows — no new fundamental data on any of the six holdings, and GEHC's mandatory post-close rebuild (discharged yesterday) needs no rework since nothing about the Sofie Biosciences situation, the FY26 guide, or the backlog picture has moved. The one item worth the team's attention is rates, not stocks: the 10-year's confirmed 5.10-5.12% settle on 9/23 is the highest since July 2007, and it starts **Day 1 of a fresh attempt** at this desk's own WACC-rebuild trigger (a close above 5% held a *full week* forces every rate-sensitive model — NVDA, OMCL, XLE, GEHC — to be rebuilt at a higher discount rate). The last two attempts (9/15-17 and briefly again mid-month) both reset before reaching a week; this one needs to be watched through roughly **9/30** before it's real. Nothing is rebuilt today on the strength of one day's close. Separately, XLE's undervaluation crossover — already flagged by this desk and BW/GS as "hope-priced" and thinning fast — has now essentially closed (+0.1% vs. yesterday's +0.8%): it is fair value in practice, and this desk expects the next up-day in oil to flip it back to overvalued. NVDA's gap narrowed meaningfully (-9.8%→-7.2%) purely on price, not on any change to the model.

---

## 1. GE HealthCare (GEHC) — price roll, no rebuild needed

Yesterday's mandatory post-close-and-hold refresh (triggered by BR's $65 line) is the standing model: base case fair value **$70.8/sh** (WACC 8.5%, g 3%), full build detail — 5-year revenue/margin/FCF projections, sensitivity table, and key assumptions — unchanged and available in yesterday's report (git history, commit for 2026-09-23). Fresh WebSearch this run found nothing new: Sofie Biosciences remains unconfirmed ("could be announced in the coming days" per the latest sourcing, still no signed deal, no financing terms — held out of the base case exactly as before); no guidance change; no backlog reversal; no CFO-transition discontinuity. GEHC's own structural-break framework (state.md rule 2) stays fully clean.

Price $66.03 (state.md, 9/24 ~09:37 ET, -0.09%) vs. fair value $70.8 → gap = (70.8 − 66.03) / 66.03 = **+7.22% undervalued**, essentially unchanged from yesterday's +6.98%.

### Verdict: **UNDERVALUED, gap ≈ +7.2% — model reaffirmed yesterday, price roll only today**
No trim, no add. GEHC remains at/above BR's ~4% target satellite weight (~4.81% of pool per today's live read) — an add still needs an explicit overweight case from BR, which no desk has made.

---

## 2. NVIDIA (NVDA) — price roll, gap narrows on price action

No new fundamental data found this run (fresh WebSearch turned up only already-priced items: a new GPU financing deal, continued AI-infrastructure demand color, the $0.25/sh dividend paying 10/1 to holders of record 9/10 — none of it moves the cash-flow picture). Live price $222.14 (state.md, 9/24 ~09:37 ET, -1.49%). Base case fair value **$206.2** (WACC 11%, g 3%, unchanged since 8/27) is untouched.

Gap: (206.2 − 222.14) / 222.14 = **-7.18% overvalued**, narrowing meaningfully from yesterday's -9.84% as the broad rate-shock-driven pullback (10yr's confirmed 5.1%+ close) pulled the stock price down toward, not away from, this desk's fair value.

### Verdict: **OVERVALUED, gap ≈ -7.2%**
Hold, no add, no trim. NVDA+OMCL combined ~20.52% of equity per state.md's 9/24 read — clean vs. the 25% trigger. Note for the desk: this is the narrowest NVDA overvaluation gap on file in several weeks, purely price-driven — worth watching if the pullback continues, since a further ~7% decline (all else equal) would flip this to fairly valued.

---

## 3. Omnicell (OMCL) — price roll, gap essentially flat

Price $32.8666 (state.md, 9/24 ~09:37 ET, -0.37%). No fresh OMCL-specific data this run; next earnings confirmed 10/29. Base case fair value **$53.89** (WACC 9%, g 3%, unchanged since 7/30).

Gap: (53.89 − 32.8666) / 32.8666 = **+63.97% upside**, essentially flat vs. yesterday's +63.08%.

### Verdict: **UNDERVALUED — widest-standing mispricing on the book, still gated**
No fresh catalyst (rule 1). The OMCL DCA accumulated-profit gate (rule 18) remains the operative timing mechanism — per state.md's 9/24 read, ~$2.52 more accumulated profit needed to fire (widened slightly from yesterday's ~$2.38 as the pool ticked back to a small negative reading), not yet there.

---

## 4. Vanguard Total Stock Market ETF (VTI) — unchanged
No change to the standing "not applicable" treatment. $376.755 (-0.39%). Defers to BR/BW on sizing and drift-band status.

## 5. Vanguard Total International Stock ETF (VXUS) — unchanged
No change to the standing "not applicable" treatment. $85.665 (-0.30%). No fair-value case to add or trim.

---

## 6. Energy Select Sector SPDR (XLE) — undervaluation crossover has essentially closed

**No material new information found this run** that would move the composite model itself — long-run Brent reversion held at $76/bbl, WACC held at 10.5%, terminal growth held at 1.5%; the sensitivity grid is unchanged from the last several reports.

**Sensitivity table — composite fair value ($/sh) by long-run Brent reversion assumption and WACC (unchanged):**

| Long-run Brent → | $65 | $70 | $75 | **$76 (base)** | $77 | $80 | $85 |
|---|---|---|---|---|---|---|---|
| WACC 9.5% | $60.7 | $64.4 | $68.1 | **$68.9** | $69.6 | $71.8 | $75.5 |
| WACC 10.5% (base) | $55.6 | $58.9 | $62.1 | **$62.8** | $63.4 | $65.3 | $68.5 |
| WACC 11.5% | $51.1 | $54.1 | $57.1 | **$57.7** | $58.3 | $60.1 | $63.0 |

vs. $62.73 live (today's only green holding, +0.58%, oil continuing to firm off Iran/Hormuz diplomacy holding steady) → gap = (62.8 − 62.73) / 62.73 = **+0.11% undervalued**, down sharply from yesterday's already-thin +0.79% and the smallest reading since the composite first crossed into undervalued territory. This is, in practical terms, **fair value** now — the crossover this desk and BW/GS have both called "hope-priced" (dependent on the Trump-Xi summit and unconfirmed Hormuz diplomacy holding) has essentially run its course.

### Verdict: **~FAIR VALUE, gap ≈ +0.1% — crossover has closed, watch for a flip to overvalued**
No trim. No unilateral add. This desk expects the next session of firm oil to push XLE back into overvalued territory on this model — at that point the "undervalued crossover" framing that has justified XLE's top-up trigger (subordinated to the OMCL DCA gate per BR's sequencing) no longer applies, and the funding-sequencing question becomes moot on the valuation leg regardless of where the OMCL gate stands. Flagging this explicitly for BR/BW's next reports.

### Key assumptions unchanged
Same as prior reports: a confirmed Hormuz reopening collapses the war premium (oil down further, XLE's gap would need spot to fall faster than the composite to stay undervalued — already the base case, not a tail case, at this valuation level); a disappointing summit or fresh escalation snaps oil back up and pushes the model further into overvalued territory. Two-name (CVX+XOM) proxy for a 24-holding basket remains a standing simplification.

---

## Rate-sensitivity note (applies to NVDA/OMCL/XLE/GEHC's WACC-based models) — Day 1 of a fresh WACC-rebuild-clock attempt

Fresh WebSearch this run confirms the 10-year Treasury **settled at ~5.10-5.12% on 9/23** (CNN: "5.1% for the first time in 19 years"; CNBC/Yahoo corroborate, citing the highest level since July 2007) — the biggest one-day move in the 10yr in nearly 18 months. This is the first *settled, multi-source-confirmed* close above this desk's 5% WACC-rebuild threshold since the 9/15-17 attempt, which reset after only two days per rule 11's addendum.

**Per this desk's own written criterion: a settled close above 5% held for a full week triggers a coordinated rebuild of every rate-sensitive model on the book (NVDA, OMCL, XLE, GEHC).** Today (9/24) is Day 1 of that clock if the close holds. This is a flag for the team to track, not a rebuild taken today — one day's close is not a week, and the two prior attempts this quarter both broke down before reaching one. If the 10yr's close stays above 5% through roughly **2026-10-01**, this desk will run the full coordinated rebuild that run (higher discount rates on all four WACC-based models would compress every fair value on this sheet — GEHC, NVDA, OMCL, and XLE's composite all move down, not just up, since a higher WACC lowers PV of future cash flows regardless of a name's current under/overvaluation direction). Rule 6a's core-up pause remains in continuous effect since 9/2 independent of this clock.

---

## Cross-check with GS screener (analysts/gs-stock-screener.md, 2026-09-24 ~09:5x ET report)

GS's rank-1 slot stays on **GEHC** this run (already held, already fully valued) — GS frames GEHC as having "absorbed yesterday's broad selloff far better than the book's other names," consistent with this desk's own read that nothing about the underlying model has changed since yesterday's rebuild. GS also flags the same 10yr rate-shock context as this desk's Day-1 WACC-clock note above, describing it as "Day 1 of a fresh attempt at MS's WACC-rebuild clock" — full agreement between desks on both the fact pattern and the framing. GS ranks SNDK #2 and MU #3, both unheld and gated (MU by this desk's own standing hard pass and JPM's WAIT call into the 9/30 print); neither requires a fresh cross-vet this run. No disagreement between desks on any held name.

## Explicit read on trader's current positions (all six held) plus GS's new #1 pick

**GEHC** (also GS's #1 pick, already held): **price roll, no rebuild needed** — fair value $70.8, gap ≈ +7.2% undervalued, essentially unchanged from yesterday's full rebuild. No trim, no add; already at/above BR's target weight, no overweight case made.
**NVDA**: hold, no add, no trim — gap narrows to ≈ -7.2% overvalued (from -9.8%) purely on price action, no model change.
**OMCL**: hold, no add — DCF discount ≈ +64.0% upside, essentially flat; DCA gate the operative timing mechanism, ~$2.52 away (widened slightly).
**VTI / VXUS**: hold, no valuation view — defer to BR/BW.
**XLE**: hold, no trim, **no unilateral add** — gap has essentially closed to ≈ +0.1% (from +0.8%), effectively fair value now; expect a flip to overvalued on the next firm oil session.

---

Sources:
- [10-year Treasury yield hits 5.1% for first time in 19 years - CNN Business](https://www.cnn.com/2026/09/23/investing/us-bond-market-fed)
- [10-year Treasury yield rockets to 19-year high - CNBC](https://www.cnbc.com/2026/09/23/treasury-yields-oil-inflation-fed.html)
- [Stock market today: Dow, S&P 500, Nasdaq tumble as 10-year Treasury yield surges to 2007 high - Yahoo Finance](https://finance.yahoo.com/markets/live/stock-market-today-wednesday-september-23-dow-sp-500-nasdaq-080556640.html)
- [GE HealthCare (GEHC) Reportedly Eyes $1B Sofie Deal - Yahoo Finance](https://finance.yahoo.com/healthcare/articles/ge-healthcare-gehc-reportedly-eyes-045718870.html)
- [GE HealthCare is said to near $1B Sofie Biosciences deal - Seeking Alpha](https://seekingalpha.com/news/4642286-ge-healthcare-is-said-to-near-1b-sofie-biosciences-deal?feed_item_type=news)
- [NVIDIA Corporation (NVDA) Stock Price, News, Quote & History - Yahoo Finance](https://finance.yahoo.com/quote/NVDA/)
- [US 10 Year Treasury Note Yield - TradingEconomics](https://tradingeconomics.com/united-states/government-bond-yield)
- Internal: trading-experiment/state.md (9/24 ~09:37 ET), analysts/gs-stock-screener.md (9/24 ~09:5x ET), analysts/bw-risk-assessment.md (9/23 ~14:41 ET), analysts/br-portfolio-builder.md (9/23 ~16:13 ET), analysts/jpm-earnings-analyzer.md (9/24 ~09:15 ET)
